| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
OSR Holdings, Inc.$0.45
+0 (+0.45%)
F 19Pipeline Score MedTech · Clinical
Market Cap
17.62 M
EPS
-0.36
P/E Ratio
-
Value Trade
792.20 K
SEC Financials
Q1 2026Dilution Risk
Revenue
484.06 K
R&D Expenses
113.15 K
Operating CF
-1.00 M
Total Assets
172.19 M
Total Liabilities
44.80 M
Equity
127.39 M
-16.33 %
Week
-14.92 %
1 Month
13.17 %
3 Month
-17.12 %
6 Month
-95.03 %
5 Year
-95.03 %
All Time
Cash Data
Cash Position
1.57 M
Monthly Burn
334.00 K
Runway
2.2 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
333.17 K
52 Week Range
0.38 - 1.79
% held by Insiders
44.72 %
% held by Institutions
0.83 %
Enterprise Value
44.54 M
Total Shares
35.13 M
Short %
8.72 %
Float Shares
19.42 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F19
Pipeline Score $0M
Pipeline ValueValuation Signal
2
Drugs Scored0.0x
rNPV / MCap Top 19%
Micro Cap (rank 749 of 923)
Percentile RankOSR Holdings, Inc. has significant pipeline risk (19/100), with $59M risk-adjusted pipeline value, led by VXM01 in Stage IV Pancreatic Cancer (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VXM01 Monoclonal antibody | Stage IV Pancreatic Cancer | Phase 1 | NCT01486329 | 17% | $59M | COMPLETED | 72 | - | - | Dec 1, 2014 | - | Jun 8, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VXM01 | recurrent glioblastoma | Phase 2a | 2025-03-26 | objective response rate: 12.0%; partial remission: 12.0%; stable disease: 4.0%; median time to progression: 2.7 months; median os: 11.1 months; overall survival range: 2.2 to 46.5 months Read More | Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma Read More | |
VXM01 | recurrent glioblastoma | Phase 2a | 2025-03-26 | objective response rate: 12.0%; partial remission: 12.0%; stable disease: 4.0%; median time to progression: 2.7 months; median os: 11.1 months; overall survival range: 2.2 to 46.5 months Read More | Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma Read More | |
VXM01 | recurrent glioblastoma | Phase 2a | 2025-03-26 | objective response rate: 12.0%; partial remission: 12.0%; stable disease: 4.0%; median time to progression: 2.7 months; median os: 11.1 months; overall survival range: 2.2 to 46.5 months Read More | Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OSRH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OSRH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OSRH▼ -38.2%on this news
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public
OSR Holdings, Inc. has entered into a definitive $815 million global license agreement with BCM Europe for the development and commercialization of VXM01, targeting VEGFR-2. The deal includes a pledge from BCM Europe to use its entire shareholding in OSRH as collateral for performance obligations, indicating strong confidence in VXM01's potential. This agreement aims to enhance value for shareholders as BCME commits to advancing the immunotherapy in the market. The collaboration reflects strategic alignment between OSRH and its major shareholder.
Read more →OSRHOSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note Bellevue, WA
OSR Holdings, Inc. has announced a strategic transaction to optimize its capital structure by retiring approximately $2.02 million in outstanding warrants through a premium-priced convertible note. This move is expected to significantly reduce potential dilution, supporting the company's equity performance and enhancing its balance sheet. The convertible note features a conversion price of $1.00 per share, which is double the company's recent closing price. This transaction marks a critical step in stabilizing OSR Holdings as it aims for NASDAQ compliance and to advance its immunotherapy and medtech initiatives.
Read more →OSRHWoori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
OSR Holdings' subsidiary, Woori IO, has signed a non-disclosure agreement with Sinopharm to explore regulatory and commercial pathways for its noninvasive glucose monitoring technology in China. This partnership aims to leverage Sinopharm's extensive distribution network in a rapidly growing diabetes market. The collaboration may lead to global multicenter trials and further strategic partnerships.
Read more →OSRH▼ -10.4%on this news
OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries
OSR Holdings, Inc. has completed its acquisition of Woori IO, enhancing its medical device and digital health platform. The historical shareholders of Woori IO have reaffirmed a three-year equity alignment with OSRH, aimed at preventing dilution. Additionally, OSRH is reviewing a potential combination of its medical device subsidiaries to create a new integrated company, leveraging the strengths of both entities.
Read more →OSRHVaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
Vaximm AG has appointed Dr. Sébastien Wieckowski as Chief Scientific Officer to enhance its oral immunotherapy platform. His extensive experience in immunology and data science is expected to drive innovation and optimize the company's lead candidate, VXM01, as it progresses into later-stage clinical trials. This strategic move aims to expand Vaximm's capabilities in oncology and other therapeutic areas.
Read more →OSRH▲ +8.3%on this news
Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones
OSR Holdings, Inc. announced that Vaximm AG has received a binding term sheet from BCM Europe AG for a global exclusive license for VXM01, their leading immunotherapy candidate. The deal includes an upfront payment of $30 million and potential milestone payments totaling up to $815 million. A third-party valuation is to be conducted to ensure the terms are fair to shareholders. This development reflects increasing confidence in VXM01's potential as a viable treatment option in the immunotherapy space.
Read more →OSRH▲ +13.7%on this news
Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings
OSR Holdings has successfully completed a share exchange that will make Woori IO a wholly-owned subsidiary. This decision, approved by Woori IO's shareholders, aims to enhance integration within the OSR Group. Woori IO is partnering with Samsung for a PoC trial in South Korea and plans to start U.S. market development with a prestigious research university. The integration into OSR is expected to strengthen Woori IO's regulatory and commercial strategies in both the Korean and U.S. markets.
Read more →OSRH▲ +23.4%on this news· ran to +49% by day 3
Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones Bellevue, WA
Vaximm AG, a subsidiary of OSR Holdings (NASDAQ: OSRH), has entered a non-binding term sheet with BCM Europe AG to negotiate an exclusive global licensing agreement for its oral cancer immunotherapy platform, VXM01. The agreement includes a $20 million upfront payment and the potential for up to $815 million in milestones. During a six-month exclusivity period, both parties will work towards finalizing a definitive agreement while Vaximm retains ownership of its intellectual property. The collaboration aims to enhance development and commercialization efforts for VXM01.
Read more →OSRHOSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care Bellevue, Washington & Seoul, South Korea
OSR Holdings, Inc. announced the acquisition of Woori IO, a pioneer in noninvasive glucose monitoring, reinforcing its commitment to biomedical innovation. The deal allows OSR to enhance its healthcare portfolio and leverage Woori's technology for a potential breakthrough in diabetes care. The acquisition is valued at under $11 million, and Woori IO will function as a subsidiary of OSR's Korean affiliate. This strategic move aims to provide a safer, more convenient alternative to traditional glucose monitoring methods while preserving existing shareholder value.
Read more →OSRH▼ -9.5%on this news
OSR HOLDINGS Innovation Headquarters | NASDAQ : OSRH Investor Update |
OSR Holdings Inc. updated investors about its corporate strategy and developments during a presentation. The company holds 100% ownership in three subsidiaries while planning to expand by acquiring another focused on noninvasive continuous glucose monitoring. Despite a recent steep decline in share price attributed to market dynamics rather than company fundamentals, OSR expects future performance to align with its business operations and market conditions. The company focuses on advancing healthcare innovations to improve health outcomes globally.
Read more →OSRH▼ -6.4%on this news
OSR Holdings Provides Transparency Update on Equity Financing Instruments
OSR Holdings, Inc. has provided a transparency update on its Equity Line of Credit (ELOC) agreement, emphasizing that future issuances will not be purely dilutive. CEO Peter Hwang highlighted that proceeds will be invested in the company's drug R&D pipeline and medical device initiatives. The company aims to protect shareholder value and believes its current share price does not reflect its intrinsic value.
Read more →OSRH▼ -20.4%on this newsshared move
OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure
OSR Holdings, Inc. has provided a strategic update on its Term Sheet with Woori IO Co., Ltd., which will make WORIO a wholly owned subsidiary. WORIO shareholders will receive OSRK shares with a conditional right to exchange for OSRH stock if the share price reaches $10.00 within three years. This transaction aims to capitalize on the growing demand for noninvasive glucose monitoring technology, positioning OSRH favorably in a market projected to exceed $40 billion by 2030.
Read more →OSRH▼ -5.9%on this news
OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring TechnologyUSA - EnglishKorea - 한국어
OSR Holdings has signed a term sheet to acquire Woori IO, a South Korean company specializing in noninvasive glucose monitoring technology. This acquisition aims to enhance OSR's portfolio in diabetes management solutions. Woori IO's technology promises pain-free glucose monitoring, potentially integrating into wearable devices. The deal includes a share exchange contingent on OSRH's stock performance.
Read more →OSRH▼ -7%on this news
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
OSR Holdings has appointed Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG. Dr. Niethammer, an expert in oncology with extensive experience in cancer immunotherapy, will lead Vaximm's clinical strategy. His leadership is anticipated to enhance the development of VXM01, an oral T-cell activator, and expand the company's oncology pipeline.
Read more →OSRHOSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AGIndia - EnglishUSA - EnglishAPAC - English
OSR Holdings, Inc. has announced a strategic roadmap for a $50 million security token offering (STO) under Regulation D, set to launch in the second half of 2025. The OSRT token will represent equity exposure and will accept various cryptocurrencies, including Bitcoin, Tether, and the Taekwondo Access Credit (TAC). The company aims to enhance investor engagement while maintaining regulatory compliance and operational integrity.
Read more →OSRHOSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG
OSR Holdings has announced a strategic roadmap for a $50 million security token offering (STO) under Regulation D, set to launch in late 2025. The OSRT token will represent equity exposure and can be purchased using Bitcoin, Tether, or the Taekwondo Access Credit (TAC) token. The initiative aims to enhance investor engagement while ensuring regulatory compliance.
Read more →OSRH▲ +5.3%on this news
OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token
OSR Holdings has signed a Memorandum of Understanding with BCM Europe AG and Taekwondo Cooperative to develop the OSRH Token, a blockchain-based security token. This initiative aims to enhance access to crypto liquidity and explore decentralized financing models. The token will accept various crypto assets, including Bitcoin and Tether, and is expected to integrate with the existing Taekwondo Access Credit infrastructure.
Read more →OSRHDarnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
Darnatein, a subsidiary of OSR Holdings, will present at the 14th International BMP Conference from May 2-6, 2025, in Philadelphia. CEO Dr. Senyon Choe will discuss their proprietary platform technology and novel biologic candidates DRT-101 and DRT-102, aimed at joint cartilage and spinal bone regeneration. This participation emphasizes Darnatein's leadership in synthetic regenerative biologics.
Read more →OSRHDarnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology
Darnatein, a subsidiary of OSR Holdings, has enhanced its intellectual property protection by securing an international patent for its osteoarthritis treatment technology in China. This patent follows a previous registration in South Korea and is a critical part of the company's efforts to protect its innovative protein-based DMOAD candidate, DRT-101. The patented technology aims to address underlying causes of osteoarthritis, potentially revolutionizing treatment options in a growing market due to an aging population. Darnatein plans to initiate Phase 1 clinical trials later this year as it completes preclinical studies.
Read more →OSRH▲ +68%on this news
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM
OSR Holdings, Inc. has entered into an $80 million Common Stock Purchase Agreement with the White Lion GBM Innovation Fund to support its innovative therapies. This funding will help speed up the development of their Vaximm platform, aimed at improving glioblastoma treatment. The partnership also integrates OSR within Innovate GBM's ecosystem, which seeks to centralize resources and enhance collaboration among various stakeholders in glioblastoma research and treatment. This strategic move is anticipated to facilitate faster development and access to promising therapies.
Read more →OSRH▲ +136.9%on this news
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Vaximm AG has announced encouraging results from its Phase 2a trial of VXM01 combined with Avelumab for recurrent glioblastoma. The trial demonstrated a good safety and tolerability profile, with 12.0% of patients showing partial remission. Notably, the combination did not introduce any new safety signals. Despite its small sample size, the study suggests that the VXM01-avelumab regimen may offer meaningful benefits for this patient population, warranting further investigation.
Read more →OSRH▼ -7.5%on this news· ran to +119% by day 1shared move
OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for...
OSR Holdings has appointed Dr. Constance Höfer as Chief Scientific Officer. With over 20 years of experience in oncology and immunology, she will lead the company's scientific strategy and innovation pipeline. Dr. Höfer's background includes significant roles at Merck Healthcare and other biopharmaceutical companies, positioning her to enhance OSR's drug development efforts.
Read more →OSRH▼ -7.5%on this news· ran to +119% by day 1shared move
OSR Holdings Appoints Dr. Constance H fer as Chief Scientific Officer
OSR Holdings, Inc. has appointed Dr. Constance H fer as its new Chief Scientific Officer. Dr. H fer, who has over 20 years of experience in oncology and immunology, will oversee the company's scientific strategy and innovation pipeline. She joins from Merck Healthcare, where she led various global drug development programs. Her appointment is expected to enhance OSR Holdings' ability to develop advanced therapeutic solutions and improve clinical development processes.
Read more →OSRH▲ +22.3%on this news
Comparison of the Three Months Ended
OSR Holdings reported a mixed financial performance for the three and nine months ended September 30, 2023, and 2024. While gross profit showed a significant increase, net sales decreased by KRW 36 million due to the termination of a key distribution agreement, leading to concerns about future revenue. Additionally, SG&A expenses rose sharply, reflecting higher operational costs, but there was a notable improvement in other income. The company anticipates continued challenges in the upcoming years until new sales strategies can be implemented.
Read more →OSRHOSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday
OSR Holdings, Inc. and OSR Holdings Co., Ltd. have announced the successful completion of their business combination, leading to the rebranding of the company. Starting February 18, 2025, the company's shares will begin trading on the Nasdaq under the ticker 'OSRH'. Following the merger, OSR Holdings, Inc. now owns about 67% of OSR's outstanding stock, with additional arrangements for further acquisitions planned for the future. The deal positions OSR to expand its portfolio of healthcare solutions, particularly in cancer treatment and age-related diseases.
Read more →OSRHOSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination
OSR Holdings, Inc. has successfully completed its business combination with OSR Holdings Co., Ltd., marking a new chapter for the company. As of February 18, 2025, shares of OSR Holdings will begin trading on the Nasdaq under the ticker 'OSRH'. The company now holds approximately 67% of OSR's outstanding stock. OSR is focused on enhancing healthcare through innovative therapies and solutions, leveraging its subsidiaries in various healthcare sectors.
Read more →OSRHBellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.
Bellevue Life Sciences Acquisition Corp. has announced the approval of its business combination with OSR Holdings Co., Ltd., along with a name change to OSR Holdings, Inc. The transaction is expected to close following necessary foreign investment approvals. With a planned trading debut on the Nasdaq under the ticker OSRH, OSR Holdings will have a controlling stake in OSR Holdings Co., Ltd. Leaders from OSR Holdings are optimistic about future growth and advancements in their healthcare initiatives.
Read more →OSRHBellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc. Bellevue Life Sciences Acquisition Corp. ("BLAC") announced today the approval of each of the proposals presented at the special meeting of its...
Bellevue Life Sciences Acquisition Corp. has received approval for its business combination with OSR Holdings Co., Ltd. The transaction is expected to close on February 14, 2025, pending foreign investment approval. Following the merger, the company will operate under the name OSR Holdings, Inc., with shares trading on Nasdaq starting February 18, 2025.
Read more →OSRHBellevue Life Sciences Acquisitions Corp. Reminds Stockholders to Vote in Favor of Extension at
Bellevue Life Sciences Acquisitions Corp. is reminding stockholders to vote on the proposed extension of the deadline for a business combination with OSR Holdings Co., Ltd. The special meeting to vote on this extension will take place on May 14, 2024. If a sufficient number of votes is not received, the company may have to commence liquidation. The extension proposal is designed to provide additional time for the completion of the business deal.
Read more →OSRHOSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp. BELLEVUE, WA & SEOUL, KR
OSR Holdings Co., Ltd. has announced a business combination agreement with Bellevue Life Sciences Acquisition Corp. Under the agreement, OSR Holdings' shares will be exchanged for BLAC common stock, giving BLAC a significant ownership stake. Upon closing, BLAC intends to rebrand itself as OSR Biosciences and list under new ticker symbols. OSR Holdings, a healthcare holding company from South Korea, operates subsidiaries in biopharmaceuticals and medical devices, aiming to enhance its position in the global healthcare market.
Read more →OSRHBellevue Life Sciences Acquisition Corp. and OSR Holdings Sign an Exclusive Letter of Intent for a Business Combination OSR Holdings expected to be public in the fourth quarter of 2023 BELLEVUE, WA & SEOUL, KR
Bellevue Life Sciences Acquisition Corp. and OSR Holdings have signed a non-binding letter of intent for a business combination, aiming for OSR Holdings to go public in the fourth quarter of 2023. OSR Holdings will be renamed OSR Biosciences, Inc. upon completion, focusing on providing innovative biomedical therapies. The merger could lead to accelerated growth and increased shareholder value, though it is subject to various conditions and potential legal challenges.
Read more →OSRHBellevue Life Sciences Acquisition Corp. Announces Separate Trading of its Shares of Common Stock, Warrants and Rights Commencing March 17 , 2023 Bellevue, Washington
Bellevue Life Sciences Acquisition Corp. announced that holders of its 6,900,000 units can begin trading the separate shares of common stock, warrants, and rights starting March 17, 2023. These units were part of the company's initial public offering, which included an over-allotment. Separated shares will trade under the ticker symbols 'BLAC,' 'BLACW,' and 'BLACR' on the Nasdaq. The company intends to focus on acquiring businesses in the healthcare industry, although the future separation of the units is subject to various risks.
Read more →OSRHBellevue Life Sciences Acquisition Corp. Announces Closing of Full Over-allotment Option Bellevue, Washington
Bellevue Life Sciences Acquisition Corp. has successfully closed the full over-allotment option granted to its IPO underwriters, which was exercised on February 17, 2023. This resulted in the issuance of an additional 900,000 units for a total of 6,900,000 units, generating gross proceeds of $69 million. The units, which include common stock, warrants, and rights, will be traded under various symbols on the Nasdaq. The company focuses on potential acquisitions in the healthcare sector.
Read more →OSRHBELLEVUE LIFE SCIENCES ACQUISITION CORP. Page Report of Independent Registered Public Accounting Firm (PCAOB ID #100) F-2 Financial Statement: Balance Sheet F-3 Notes to Financial Statement F-4 F-1 Report of Independent
Bellevue Life Sciences Acquisition Corp. published its financial report indicating its balance sheet as of February 14, 2023. The report reveals liquidity challenges, as the company must secure additional funding to avoid ceasing operations by November 2023. Additionally, the company reported a significant accumulated deficit and emphasizes its reliance on completing a business combination to generate revenues. Without successful fundraising, the company faces a mandatory liquidation scenario.
Read more →OSRHBellevue Life Sciences Acquisition Corp. Announces Pricing of $60 Million Initial Public Offering Bellevue, Washington
Bellevue Life Sciences Acquisition Corp. has announced the pricing of its initial public offering at $60 million, with 6,000,000 units offered at $10.00 each. The units will begin trading on Nasdaq under the ticker symbol BLACU on February 10, 2023. Each unit includes one share of common stock, a redeemable warrant, and a right for fractional shares upon completion of a business combination. The offering is expected to close on February 14, 2023, subject to customary conditions. The company aims to focus its acquisition efforts on the healthcare sector.
Read more →Competitive Position
How OSRH ranks across every disease it competes inCompetitive Position is a premium feature
See how OSRH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial